No Data
No Data
BofA Securities Maintains Bluebird Bio(BLUE.US) With Buy Rating
BofA Securities analyst Jason Gerberry maintains $bluebird bio(BLUE.US)$ with a buy rating.According to TipRanks data, the analyst has a success rate of 44.4% and a total average return of -0.6%
Bluebird Bio (BLUE) Gets a Buy From Bank of America Securities
Bluebird Bio Reports Inducement Grant to CFO James Sterling Under Nasdaq Listing Rule 5635(c)(4)
bluebird bio, Inc. (NASDAQ:BLUE) today announced that the Compensation Committee of the Company's Board of Directors approved an inducement grant of stock options to purchase a total of 300,000 shares of common stock to
2Flo Ventures Announces Addition of Renowned Life Sciences Executive Charlotte Jones-Burton, MD, MS as a Partner
2Flo Ventures, an emerging venture capital firm and startup studio focused on the discovery, development, and commercialization of healthcare...
BioLineRx Stock Jumps 14% on St. Jude Clinical Trial for Mitoxafortide
Bluebird Bio Announces CFO Transition and Compensation Details
No Data
MARKET-TEST-DUMMY : Seems like more time is needed but heading on the right path to getting patients in line. They seem optimistic as far as the company goes. I'm sure there's a lot of bureaucracy and red tape to getting payments. Like anything else, it should get easier as they go or as they set precedent, so it seems. Not all QTC's are equal and interesting some don't want to be listed on their website though. Wonder if that's a product thing or just not in need of an another patient. Either way, appreciate ya pointing this out. Will be keeping eye on this one too.
TrytosaveabitOP MARKET-TEST-DUMMY: You’re very welcome! Where ya been. I was thinking wow his work musta really picked up. Well at least I’m hoping it was that and nothings gone bad! Anyways good to see ya![undefined undefined](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36)